Description

EKF Diagnostics Holdings plc, a company founded in 1990 and based in Cardiff, United Kingdom, operates as an international supplier of diagnostic solutions. The firm excels in the development, manufacturing, and distribution of a wide array of diagnostic instruments, chemical reagents, and associated products. Its extensive market reach spans across Europe, the Middle East, the Americas, Asia, Africa, and beyond. The company's product lineup addresses various critical diagnostic needs. This includes a range of hemoglobin analysis devices, such as the handheld DiaSpect Tm and the quantitative Hemo Control. EKF also provides advanced glucose and lactate analyzers like the Biosen C-Line series, alongside point-of-care solutions for diabetes management, exemplified by the Quo-Lab A1c and Quo-Test A1c. Beyond these, their offerings extend to specialized diagnostic tools: the Creamatocrit Plus for assessing lipid concentration in mothers' milk, QuPID and True20 pregnancy tests, and the STAT-Site M Beta-hydroxybutyrate analyzer. EKF further supplies a comprehensive suite of clinical chemical analyzers and reagents, designed for monitoring conditions such as ketosis, glycated albumin, glycated serum protein, and utilizing markers like Procalcitonin for bacterial infections and sepsis. Additional provisions include immunoassay kits, general chemistry analyzers like the Altair 240, micro centrifuges, the Uri-Trak 120 urine analyzer, and dedicated kits and services for COVID-19. The company also offers its manufacturing capabilities as contract solutions to third-party businesses and delivers professional laboratory services.